Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial

Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects o...

Full description

Bibliographic Details
Main Authors: Leila Zareian, Amir Azarhomayoun, Maysam Alimohamadi, Mohammadreza Khajavi, Soodeh Razeghi-Jahromi
Format: Article
Language:English
Published: Guilan University of Medical Sciences 2017-09-01
Series:Iranian Journal of Neurosurgery
Subjects:
Online Access:http://irjns.org/browse.php?a_code=A-10-181-1&slc_lang=en&sid=1
id doaj-728224ab00ac4429b209ed8c274e10eb
record_format Article
spelling doaj-728224ab00ac4429b209ed8c274e10eb2021-04-02T19:16:28ZengGuilan University of Medical SciencesIranian Journal of Neurosurgery2423-64972423-68292017-09-01325157Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical TrialLeila Zareian0Amir Azarhomayoun1Maysam Alimohamadi2Mohammadreza Khajavi3Soodeh Razeghi-Jahromi4 MSc, Animal Physiology Department, Basic Sciences Faculty, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran MD, Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran MD, Brain and Spinal Cord Injury Research Center (BASIR), Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran MD, Department of Anesthesiology, Sina hospital, Tehran University of Medical Sciences, Tehran, Iran PhD, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects of epigallocatechin-3-gallate on the early clinical outcome and serum S100B levels (biomarker for brain tissue damage severity) in patients with moderate to severe traumatic brain injury. Methods and Materials/Patients: Thirty patients with moderate to severe traumatic brain injury admitted to the intensive care unit were enrolled. The patients were randomly allocated to treatment with either a daily oral dose of 400 mg epigallocatechin-3-gallate or placebo (distilled water) for seven days. The main outcome measures were duration of mechanical ventilation and ICU stay, Glasgow Coma Scale, and S100B protein level. Results: The results revealed a significant improvement in consciousness level after seven days in the epigallocatechin-3-gallate group (2.93±3.9 unit improvement in GCS versus 0.14±3.05 reduction in GCS, p-value:0.033). There was also a significantly shorter duration of mechanical ventilation in the epigallocatechin-3-gallate compared to the control group (5.1 days versus 9.8 days, p-value:0.02). Reduction of the serum S100B level was slightly higher in the epigallocatechin-3-gallate group (23.96 versus 18.6 pg/ml) but the difference was not statistically significant. Conclusion: Epigallocatechin-3-gallate supplementation had beneficial effects on consciousness level of the patients with moderate to severe traumatic brain injury in the acute phase.http://irjns.org/browse.php?a_code=A-10-181-1&slc_lang=en&sid=1Epigallocatechin-3-gallateHead TraumaNeuroprotectionS100B ProteinTraumatic Brain Injury
collection DOAJ
language English
format Article
sources DOAJ
author Leila Zareian
Amir Azarhomayoun
Maysam Alimohamadi
Mohammadreza Khajavi
Soodeh Razeghi-Jahromi
spellingShingle Leila Zareian
Amir Azarhomayoun
Maysam Alimohamadi
Mohammadreza Khajavi
Soodeh Razeghi-Jahromi
Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
Iranian Journal of Neurosurgery
Epigallocatechin-3-gallate
Head Trauma
Neuroprotection
S100B Protein
Traumatic Brain Injury
author_facet Leila Zareian
Amir Azarhomayoun
Maysam Alimohamadi
Mohammadreza Khajavi
Soodeh Razeghi-Jahromi
author_sort Leila Zareian
title Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
title_short Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
title_full Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
title_fullStr Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
title_full_unstemmed Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
title_sort impact of acute phase epigallocatechin-3-gallate supplementation on consciousness and s100b serum levels in tbi patients: a double blind randomized clinical trial
publisher Guilan University of Medical Sciences
series Iranian Journal of Neurosurgery
issn 2423-6497
2423-6829
publishDate 2017-09-01
description Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects of epigallocatechin-3-gallate on the early clinical outcome and serum S100B levels (biomarker for brain tissue damage severity) in patients with moderate to severe traumatic brain injury. Methods and Materials/Patients: Thirty patients with moderate to severe traumatic brain injury admitted to the intensive care unit were enrolled. The patients were randomly allocated to treatment with either a daily oral dose of 400 mg epigallocatechin-3-gallate or placebo (distilled water) for seven days. The main outcome measures were duration of mechanical ventilation and ICU stay, Glasgow Coma Scale, and S100B protein level. Results: The results revealed a significant improvement in consciousness level after seven days in the epigallocatechin-3-gallate group (2.93±3.9 unit improvement in GCS versus 0.14±3.05 reduction in GCS, p-value:0.033). There was also a significantly shorter duration of mechanical ventilation in the epigallocatechin-3-gallate compared to the control group (5.1 days versus 9.8 days, p-value:0.02). Reduction of the serum S100B level was slightly higher in the epigallocatechin-3-gallate group (23.96 versus 18.6 pg/ml) but the difference was not statistically significant. Conclusion: Epigallocatechin-3-gallate supplementation had beneficial effects on consciousness level of the patients with moderate to severe traumatic brain injury in the acute phase.
topic Epigallocatechin-3-gallate
Head Trauma
Neuroprotection
S100B Protein
Traumatic Brain Injury
url http://irjns.org/browse.php?a_code=A-10-181-1&slc_lang=en&sid=1
work_keys_str_mv AT leilazareian impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial
AT amirazarhomayoun impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial
AT maysamalimohamadi impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial
AT mohammadrezakhajavi impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial
AT soodehrazeghijahromi impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial
_version_ 1721549278604689408